|
Day One November 18
Emerging Company Partnering Showcase
The session is designed to showcase early stage companies which offer interesting possibilities for partnering and collaboration. Each company will present their capabilities and what sets them apart from competitors and what types of deals they are interested in considering.
7:30 Pre-Conference Session Registration
8:20 Moderator's Opening
Remarks
| 8:30 Platform Companies
|
3DM, Inc.
PuraMatrix, 3DM’s award-winning product line of synthetic self-assembling peptide
hydrogels, is the leading commercial synthetic scaffold for 3D cell culture.
Genodive
Genodive’s major core platform is to identify disease-susceptible genes using microsatellite markers, based on the association analysis, which are poled on human whole genome.
Reify Corporation
Reify’s Visible Discovery™ platform combines proprietary machine learning and signal processing technologies with world-class biological research to assess the effects of small molecules on critical molecular pathways in their native cellular environments.
TransTech Pharma Inc
TransTech Pharma’s highly automated and fully integrated drug discovery process consists of a series of proprietary software coupled with highly sophisticated chemistry and biology approaches.
|
|
|
| 9:45 Critique Panel - Comments and Feedback
|
 |
Mason Tenaglia, Vice President, Pharmaceuticals, Charles River Associates
Robert Gould, Vice President, Licensing & External
Research, Merck Research Labs
Lisa Gray, Managing Partner, Phoenix IP Ventures (former
Director at GSK Ventures)
Michael Lytton, J.D., M.Sc., General Partner, Oxford
Bioscience Partners |
| 10:15 Refreshment Break |
| 10:45 Therapeutics Companies
|
Dynogen Pharmaceuticals Inc.
Dynogen is focused on developing drugs for genitourinary (GU) and gastrointestinal (GI) disorders, including overactive bladder
(OAB), irritable bowel syndrome (IBS), and sexual dysfunction.
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals is a cancer therapeutics company focused on developing and commercializing innovative products to meet the high unmet medical needs in cancer management.
Quintessence Biosciences, Inc.
Quintessence’s EVade™ technology provides the world’s only cancer therapy derived from a natural human protein, a
ribonuclease. |
|
|
| 12:00 Critique Panel - Comments and Feedback
|
|
Mason Tenaglia, Vice President, Pharmaceuticals, Charles River Associates
Robert Gould, Vice President, Licensing & External Research, Merck Research Labs
Lisa Gray, Managing Partner, Phoenix IP Ventures (former Director at GSK Venture
Michael Lytton, J.D., M.Sc., General Partner, Oxford Bioscience Partners |
12:30 Break Out Session & Lunch
Presenters will be at tables providing an opportunity for the audience to meet with companies and explore the potential for collaboration.
Main Conference
12:45 Main Conference Registration
1:50 Chairperson's Opening Remarks
2:00 Symbiosis of Large Pharma and Biotech: Getting the Interactions Right Through to Due Diligence
• Market environment
• Steps to take when approaching a potential partnership
• Streamlining the evaluation process and engaging in due diligence
William Mann, Director, Global Search and Evaluation, Global Business Development, Novartis
| 2:45 One-to-One Meetings and Networking Refreshment Break |
|
3:30 Improving the ROI of Technology Collaborations
• Building a robust business case
• Strategies for equitable distribution of "gain"
• Maximizing global impact through collaboration management
Otto Ritter, Associate Director, Bioinformatics, AstraZeneca Pharmaceuticals, Inc.
4:15 The Impact of Out-Licensing Compounds
• Creating a model that quantifies the value of a potential partnership
• Criteria used to determine when out-licensing is the right strategy for a project
• Recognizing the right partner
• How can biotech and big pharma best leverage each others' skills?
• How will the partnering landscape look in 10 years?
Darren Braccia, Associate Director, Business Development, Vertex Pharmaceuticals, Inc.
 |
5:00 Networking Cocktail Reception
|
|
6:00 Close of Day One
|
6:15 Exclusive Pharmaceutical Strategy Series
Networking Dinner at Sidney's Grill
|
|
|
